Cardiovascular DiseaseNCT02400879
Remifentanil Anesthesia and Postoperative BIS in Cardiac Surgery
A study testing Remifentanil and sevoflurane and sufentanil in people with Cardiovascular Disease, run by Konkuk University Medical Center.
Trial summary
Background: Although remifentanil based anesthesia has been preferred for fast-track cardiac anesthesia, its recovery profile in cognitive function has not been investigated. Authors determined postoperative Bispectral index (BIS) score as well as extubation time after remifentanil-based propofol-supplemented… Read more about this study
- Who is it for?
- Ages 19 to 70 years
- Conditions the study is for
- Cardiovascular Disease
- What is being tested?
- Remifentanil and sevoflurane and sufentanil
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 38 participants
- Where
- No sites listed yet
- Study dates
- Oct 2015to Oct 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients undergoing cardiac valve repair or replacement surgery under moderate hypothermic cardiopulmonary bypass (CPB).
- All patients should provide written informed consents
Who cannot join
- Preoperative exclusion criteria
- urgent or emergent surgery,
- left ventricle (LV) ejection fraction < 50%,
- application of intraaortic balloon pump (IABP),
- myocardial infarction,
- neurologic deficit,
Show all 20Show fewer
- hepatic or renal impairment,
- pacing,
- inotropic medication,
- neurologic deficit.
- Intraoperative exclusion criteria
- CPB application > 250 min,
- transfused of packed red blood cell (pRBC) > 5 units,
- post-CPB use of double inotropic support > 30 min ,
- post-CPB pacing,
- IABP
- IABP
- postoperative hemodialysis,
- excessive bleeding > 750 ml during postoperative 6 hour,
- reoperation due to excessive bleeding.
About this study
Official title: Comparisons of Postoperative BIS Profile and Extubation Time After Valvular Heart Surgery: Remifentanil-based Propofol-supplemented Versus Sevoflurane-sufentanil Balanced Anesthesia Regimen
Background: Although remifentanil based anesthesia has been preferred for fast-track cardiac anesthesia, its recovery profile in cognitive function has not been investigated. Authors determined postoperative Bispectral index (BIS) score as well as extubation time after remifentanil-based propofol-supplemented anesthesia and compared them with those after conventional balanced sevoflurane-sufentanil anesthesia.
Methods: Patients undergoing cardiac surgery using moderate hypothermic cardiopulmonary bypass (CPB) will be randomly allocated to get remifentanil-based propofol-supplemented (Group R) or conventional sevoflurane-sufentanil regimen (Group C) in the study period. For anesthetic induction and maintenance, fixed target controlled infusion (TCI) of remifentanil (plasma concentration 20 ng/ml) and TCI-propofol for maintaining BIS score 40-60 (effect concentration 0.8-1.5 μg/ml) in Group R, and TCI-sufentanil (Cp 0.4- 0.8 ng/ml) and sevoflurane inhalation for maintaining 80-120 % of baseline BP and BIS < 60 (< 1.5 MAC) in Group C, respectively.
Authors will analyze postoperative recovery of cognitive function by using BIS after the use of remifentanil-based propofol-supplemented anesthesia for cardiac surgery and to compare them to those after the use of conventional balanced sevoflurane-sufentanil anesthesia.
Read the detailed description
Backgrounds Since opioid-based anesthesia does not produce dose-dependent myocardial depression, it has been applied for patients undergoing cardiac surgery with myocardial dysfunction.
However, prolonged use of conventional opioids in a large dosage delays patient's postoperative recovery due to their longer half-life and accumulation of their metabolites.
Fast-track cardiac anesthesia which reducing the duration of postoperative mechanical ventilation and length of stay (LOS) in the intensive care unit (ICU) is beneficial not only in reducing ventilator-related complications and medical expense but in improving patient's outcome.
For this purpose, in addition to supplementation of neuraxial blockade, use of short-acing opioid, such as remifentanil, has been advocated for cardiac anesthesia. Remifentanil is an ultra-short acting opioid and provides not only stable hemodynamics, as other opioid does, and but fast recovery, even after prolonged use in a large dosage. In further, recent investigations showed that remifentanil provides preconditioning effect in myocardial ischemia injury during cardiac surgery, as like in the use of volatile anesthetics including sevoflurane.
Remifentanil vs volatile anesthetics In spite of the importance of recovery of cognitive function on whole postoperative clinical features, most investigations have evaluated only the postoperative respiratory profile in determining the speed of postoperative recovery specific to the choice of anesthesia regimen.
Bispectral index (BIS) monitoring has been used to monitor sedation depth, to avoid introperative awareness and to adjust the dosage of intraoperative hypnotics. Several investigations tried to find BIS's efficacy in managing sedation of critically ill patients. In spite of some controversies, BIS monitoring seem to be beneficial: it does not require additional stimuli to determine sedation level which is essential in other subjective modalities, such as Ramsay score, and usually compromises the already instituted patient's sedation level.
Authors will analyze postoperative recovery of cognitive function by using BIS as well as respiratory profiles after the use of remifentanil-based propofol-supplemented anesthesia for cardiac surgery and to compare them to those after the use of conventional balanced sevoflurane-sufentanil anesthesia.
Methods Population and Study Protocol After obtaining Institutional Review Board approval and informed consents from the patients, they are prospectively studied among patients undergoing cardiac valve repair or replacement surgery under moderate hypothermic cardiopulmonary bypass (CPB).
During the study period (6 months), at least, forty patients are randomly allocated into following one of two groups using sealed envelopes: remifentanil-based propofol-supplemented anesthesia regimen is employed in Group R and conventional balanced sevoflurane-sufentanil anesthesia regimen in Group C, respectively.
Preoperative and intraoperative exclusion criteria Preoperative exclusion criteria 1) urgent or emergent surgery, 2) left ventricle (LV) ejection fraction < 50%, 3) application of intraaortic balloon pump (IABP), 4) myocardial infarction, 5) neurologic deficit, 6) hepatic or renal impairment, 7) pacing, 8) inotropic medication, 9) neurologic deficit.
Intraoperative exclusion criteria
- CPB application > 250 min, 2) transfused of packed red blood cell (pRBC) > 5 units, 3) post-CPB use of double inotropic support > 30 min , 4) post-CPB pacing, 5) IABP 6) IABP 7) postoperative hemodialysis, 8) excessive bleeding > 750 ml during postoperative 6 hour, 9) reoperation due to excessive bleeding.
All data were collected by trained observers who did not participate in patient care and who were blinded to the current study.
Anesthesia regimen After establishing routine invasive arterial blood pressure and noninvasive patient monitoring such as pulse oximetry (SpO2), electrocardiography, bispectral index (BIS) and cerebral oximetry, anesthesia is induced by two staff anesthesiologist (AA and BB) using a target controlled infusion (TCI) of propofol (effect site concentration, Ce, of 2.0 µg/ml) and remifentanil (plasma concentration, Cp, of 20 ng/ml with the time to reach target concentration of 7 min) in Group R (by AA), and anesthesia is induced by bolus injection of thiopental sodium 3-4 mg/kg and maintained using TCI- sufentanil (Cp of 0.4 ng/ml) in Group C (by BB). Muscle relaxation and tracheal intubation is facilitated by bolus rocuronium under the guidance of peripheral neuromuscular transmission.
For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce < 2.0 µg/ml) for maintaining BIS 40-60 in Group R [14], and TCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS < 60 in Group C, respectively. Rocuronium is continuously infused (3 µg/kg/min) in both groups.
Controlled ventilation of O2/air mixture (FiO2 0.5-0.6) is performed with following setting of anesthesia ventilator (ADU™, Datex-Ohmeda, Finland): tidal volume of 7 ml/ideal body weight (calculated by obsolete formulas), respiratory rate maintain normocarbia (end-tidal CO2 tension 35-40 mmHg) and inspiratory:expiratory ratio of 1:2.
Pulmonary artery catheter (Swan-GanzCCOmboCCO/SvO2, Edwards Lifesciences, Irvine, USA) and a probe of transesophageal echocardiography were placed after anesthesia induction.
If high BIS score (> 60) persisted against the increase of sevoflurane to 1.5 MAC in Group C or Ce of propofol to 2.0 μg/ml in Group R, bolus midazolam 2 mg is administered.
Surgery and CPB regimen All surgery is performed by one surgeon and 4 surgical assistants. After performing sternotomy and administration of heparin 300 units/kg, arterial and venous cannulations for CPB are performed at activated clotting time (ACT) > 450 sec and CPB was conducted using reservoir, membrane oxygenator, roller pump and heat exchanger. Priming volume for CPB was composed of normal saline, 20% mannitol, NaHCO3, 20% albumin, heparin, antibiotics and calcium gluconate. The flow of CPB is initiated at 60 ml/kg/min and adjusted by the current hemodilution and temperature.
Antegrade or retrograde administration of cold cardioplegic solution (20 ml/kg) consisting of drained patient's blood, NaCl 6.43 g/L, KCl 1.193 g/L, CaCl2 0.176 g/L and MgCl2 3.253 g/L (pH 7.4 at 4 - 8 °C) is applied as appropriate for cardiac protection after application of aortic cross clamp (ACC).
Transfer to intensive care unit (ICU) and postoperative pain control After surgery, the patients are transferred to the ICU in intubated status and received controlled or assisted ventilation till the time of extubation. In Group R, remifentanil 0.25-0.3 μg /kg/min is continued till the time of extubation.
For postoperative pain control, the intravenous patient control analgesia consisting of alfentanil, ketorolac, and ondansetron is started at the time of sterna closure in Group C or at 20 min before extubation in Group R, respectively.
Protocols of ventilator weaning and extubation The mode of ventilator is converted from volume controled ventilation (CMV) to synchronized intermittent mandatory ventilation (SIMV) when the following criteria were achieved: stable hemodynamics, self respiration, and the respiratory rate 10-25 breaths/min [15].
The patients are extubated when the following criteria are achieved: awake state, stable hemodynamics, normal airway reflex, respiratory rate 10-25 breath/min, SpO2 > 95% at FiO2 < 0.6, pH ≥ 7.3 and PaCO2 < 55 mmHg.
Measurements Operation time, CPB time, ACC time, intraoperative fluid administration quantity, transfusion requirements, intraoperative urine output (UO), preoperative and postoperative hematocrit (Hct) and preoperative and postoperative PaO2/FiO2 ratio are recorded.
The duration from the end of surgery to the time of achieving BIS score > 80 (persisting > 3 min) (T-BIS80) [16], the duration from end of surgery to the time of initiating SIMV (T-SIMV) and the duration from the end of surgery to the time of extubation (T-extubation) are measured.
Statistical analysis The primary outcome variables are T-BIS80, T-SIMV, and T-extubation. Statistics are performed using the program Sigmastat ver.3.1(Systat Software Inc, San Jose, USA). Continuous variables were analyzed by a t-test, while categorical variables are by a chi-square test between two groups. The data collected are expressed as mean and standard deviation, numbers of patients or absolute numbers. A P value < 0.05 is considered significant.
- Conditions
- Cardiovascular Disease
- Being tested
- Remifentanil, sevoflurane and sufentanil
- Keywords
- bispectral index, cardiac surgery, recovery, remifentanil
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RemifentanilDrug
Also called ultiva, GSK
administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
sevoflurane and sufentanilDrug
Also called sevorane and sufental
administering sevoflurane and sufentanil for anesthesia maintenance
| Study group | Role | What they receive |
|---|---|---|
| Remifentanil | Active comparator | For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce < 2.0 µg/ml) for maintaining BIS 40-60 Receives: Drug: Remifentanil |
| sevoflurane and sufentanil | Placebo comparator | TCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS < 60 Receives: Drug: sevoflurane and sufentanil |
What is being measured
The primary outcome is the main question the study is designed to answer.
time to achieving BIS>80
The duration from the end of surgery to the time of achieving BIS score > 80 (BIS>80 persisting > 3 min)
Measured: 5 min
Secondary outcomes (2)
time to achieve SIMV ventilation mode
the duration from end of surgery to the time of initiating SIMV (T-SIMV)
Measured: 5 min
time to achieve extubation
the duration from the end of surgery to the time of extubation (T-extubation)
Measured: 5 min
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2015 (estimated)
- Study startOct 2015
- Primary completionOct 2015
- Study completionOct 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 38 participants (actual)
Sponsor and investigators
- Lead sponsor
- Konkuk University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tae-Yop Kim, MD PhD, Konkuk University Medical Center
- Investigators
- Tae-Yop Kim, MD, PhD, Principal investigator, Konkuk Univeristy Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02400879
- Sponsor's protocol ID
- KUH-1160080
- Status last verified
- Aug 2020
- First submitted
- 15 Mar 2015
- Last updated
- 19 Aug 2020
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparisons of Postoperative BIS Profile and Extubation Time After Valvular Heart Surgery: Remifentanil-based Propofol-supplemented Versus Sevoflurane-sufentanil Balanced Anesthesia Regimen
- ClinicalTrials.gov ID
- NCT02400879
- Acronym / sponsor ID
- KUH-1160080
- Conditions
- Cardiovascular Disease
- Keywords
- bispectral index, cardiac surgery, recovery, remifentanil
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 38 participants (actual)
- Lead sponsor
- Konkuk University Medical CenterUniversity, hospital or other
- Study start
- Oct 2015 (actual)
- Primary completion
- Oct 2015 (actual)
- Study completion
- Oct 2016 (actual)
- First posted
- 27 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Although remifentanil based anesthesia has been preferred for fast-track cardiac anesthesia, its recovery profile in cognitive function has not been investigated. Authors determined postoperative Bispectral index (BIS) score as well as extubation time after remifentanil-based propofol-supplemented anesthesia and compared them with those after conventional balanced sevoflurane-sufentanil anesthesia.
Methods: Patients undergoing cardiac surgery using moderate hypothermic cardiopulmonary bypass (CPB) will be randomly allocated to get remifentanil-based propofol-supplemented (Group R) or conventional sevoflurane-sufentanil regimen (Group C) in the study period. For anesthetic induction and maintenance, fixed target controlled infusion (TCI) of remifentanil (plasma concentration 20 ng/ml) and TCI-propofol for maintaining BIS score 40-60 (effect concentration 0.8-1.5 μg/ml) in Group R, and TCI-sufentanil (Cp 0.4- 0.8 ng/ml) and sevoflurane inhalation for maintaining 80-120 % of baseline BP and BIS < 60 (< 1.5 MAC) in Group C, respectively.
Authors will analyze postoperative recovery of cognitive function by using BIS after the use of remifentanil-based propofol-supplemented anesthesia for cardiac surgery and to compare them to those after the use of conventional balanced sevoflurane-sufentanil anesthesia.
Detailed description
Backgrounds Since opioid-based anesthesia does not produce dose-dependent myocardial depression, it has been applied for patients undergoing cardiac surgery with myocardial dysfunction.
However, prolonged use of conventional opioids in a large dosage delays patient's postoperative recovery due to their longer half-life and accumulation of their metabolites.
Fast-track cardiac anesthesia which reducing the duration of postoperative mechanical ventilation and length of stay (LOS) in the intensive care unit (ICU) is beneficial not only in reducing ventilator-related complications and medical expense but in improving patient's outcome.
For this purpose, in addition to supplementation of neuraxial blockade, use of short-acing opioid, such as remifentanil, has been advocated for cardiac anesthesia. Remifentanil is an ultra-short acting opioid and provides not only stable hemodynamics, as other opioid does, and but fast recovery, even after prolonged use in a large dosage. In further, recent investigations showed that remifentanil provides preconditioning effect in myocardial ischemia injury during cardiac surgery, as like in the use of volatile anesthetics including sevoflurane.
Remifentanil vs volatile anesthetics In spite of the importance of recovery of cognitive function on whole postoperative clinical features, most investigations have evaluated only the postoperative respiratory profile in determining the speed of postoperative recovery specific to the choice of anesthesia regimen.
Bispectral index (BIS) monitoring has been used to monitor sedation depth, to avoid introperative awareness and to adjust the dosage of intraoperative hypnotics. Several investigations tried to find BIS's efficacy in managing sedation of critically ill patients. In spite of some controversies, BIS monitoring seem to be beneficial: it does not require additional stimuli to determine sedation level which is essential in other subjective modalities, such as Ramsay score, and usually compromises the already instituted patient's sedation level.
Authors will analyze postoperative recovery of cognitive function by using BIS as well as respiratory profiles after the use of remifentanil-based propofol-supplemented anesthesia for cardiac surgery and to compare them to those after the use of conventional balanced sevoflurane-sufentanil anesthesia.
Methods Population and Study Protocol After obtaining Institutional Review Board approval and informed consents from the patients, they are prospectively studied among patients undergoing cardiac valve repair or replacement surgery under moderate hypothermic cardiopulmonary bypass (CPB).
During the study period (6 months), at least, forty patients are randomly allocated into following one of two groups using sealed envelopes: remifentanil-based propofol-supplemented anesthesia regimen is employed in Group R and conventional balanced sevoflurane-sufentanil anesthesia regimen in Group C, respectively.
Preoperative and intraoperative exclusion criteria Preoperative exclusion criteria 1) urgent or emergent surgery, 2) left ventricle (LV) ejection fraction < 50%, 3) application of intraaortic balloon pump (IABP), 4) myocardial infarction, 5) neurologic deficit, 6) hepatic or renal impairment, 7) pacing, 8) inotropic medication, 9) neurologic deficit.
Intraoperative exclusion criteria
- CPB application > 250 min, 2) transfused of packed red blood cell (pRBC) > 5 units, 3) post-CPB use of double inotropic support > 30 min , 4) post-CPB pacing, 5) IABP 6) IABP 7) postoperative hemodialysis, 8) excessive bleeding > 750 ml during postoperative 6 hour, 9) reoperation due to excessive bleeding.
All data were collected by trained observers who did not participate in patient care and who were blinded to the current study.
Anesthesia regimen After establishing routine invasive arterial blood pressure and noninvasive patient monitoring such as pulse oximetry (SpO2), electrocardiography, bispectral index (BIS) and cerebral oximetry, anesthesia is induced by two staff anesthesiologist (AA and BB) using a target controlled infusion (TCI) of propofol (effect site concentration, Ce, of 2.0 µg/ml) and remifentanil (plasma concentration, Cp, of 20 ng/ml with the time to reach target concentration of 7 min) in Group R (by AA), and anesthesia is induced by bolus injection of thiopental sodium 3-4 mg/kg and maintained using TCI- sufentanil (Cp of 0.4 ng/ml) in Group C (by BB). Muscle relaxation and tracheal intubation is facilitated by bolus rocuronium under the guidance of peripheral neuromuscular transmission.
For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce < 2.0 µg/ml) for maintaining BIS 40-60 in Group R [14], and TCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS < 60 in Group C, respectively. Rocuronium is continuously infused (3 µg/kg/min) in both groups.
Controlled ventilation of O2/air mixture (FiO2 0.5-0.6) is performed with following setting of anesthesia ventilator (ADU™, Datex-Ohmeda, Finland): tidal volume of 7 ml/ideal body weight (calculated by obsolete formulas), respiratory rate maintain normocarbia (end-tidal CO2 tension 35-40 mmHg) and inspiratory:expiratory ratio of 1:2.
Pulmonary artery catheter (Swan-GanzCCOmboCCO/SvO2, Edwards Lifesciences, Irvine, USA) and a probe of transesophageal echocardiography were placed after anesthesia induction.
If high BIS score (> 60) persisted against the increase of sevoflurane to 1.5 MAC in Group C or Ce of propofol to 2.0 μg/ml in Group R, bolus midazolam 2 mg is administered.
Surgery and CPB regimen All surgery is performed by one surgeon and 4 surgical assistants. After performing sternotomy and administration of heparin 300 units/kg, arterial and venous cannulations for CPB are performed at activated clotting time (ACT) > 450 sec and CPB was conducted using reservoir, membrane oxygenator, roller pump and heat exchanger. Priming volume for CPB was composed of normal saline, 20% mannitol, NaHCO3, 20% albumin, heparin, antibiotics and calcium gluconate. The flow of CPB is initiated at 60 ml/kg/min and adjusted by the current hemodilution and temperature.
Antegrade or retrograde administration of cold cardioplegic solution (20 ml/kg) consisting of drained patient's blood, NaCl 6.43 g/L, KCl 1.193 g/L, CaCl2 0.176 g/L and MgCl2 3.253 g/L (pH 7.4 at 4 - 8 °C) is applied as appropriate for cardiac protection after application of aortic cross clamp (ACC).
Transfer to intensive care unit (ICU) and postoperative pain control After surgery, the patients are transferred to the ICU in intubated status and received controlled or assisted ventilation till the time of extubation. In Group R, remifentanil 0.25-0.3 μg /kg/min is continued till the time of extubation.
For postoperative pain control, the intravenous patient control analgesia consisting of alfentanil, ketorolac, and ondansetron is started at the time of sterna closure in Group C or at 20 min before extubation in Group R, respectively.
Protocols of ventilator weaning and extubation The mode of ventilator is converted from volume controled ventilation (CMV) to synchronized intermittent mandatory ventilation (SIMV) when the following criteria were achieved: stable hemodynamics, self respiration, and the respiratory rate 10-25 breaths/min [15].
The patients are extubated when the following criteria are achieved: awake state, stable hemodynamics, normal airway reflex, respiratory rate 10-25 breath/min, SpO2 > 95% at FiO2 < 0.6, pH ≥ 7.3 and PaCO2 < 55 mmHg.
Measurements Operation time, CPB time, ACC time, intraoperative fluid administration quantity, transfusion requirements, intraoperative urine output (UO), preoperative and postoperative hematocrit (Hct) and preoperative and postoperative PaO2/FiO2 ratio are recorded.
The duration from the end of surgery to the time of achieving BIS score > 80 (persisting > 3 min) (T-BIS80) [16], the duration from end of surgery to the time of initiating SIMV (T-SIMV) and the duration from the end of surgery to the time of extubation (T-extubation) are measured.
Statistical analysis The primary outcome variables are T-BIS80, T-SIMV, and T-extubation. Statistics are performed using the program Sigmastat ver.3.1(Systat Software Inc, San Jose, USA). Continuous variables were analyzed by a t-test, while categorical variables are by a chi-square test between two groups. The data collected are expressed as mean and standard deviation, numbers of patients or absolute numbers. A P value < 0.05 is considered significant.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Remifentanil | Active comparator | Drug: RemifentanilFor anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce < 2.0 µg/ml) for maintaining BIS 40-60 |
| sevoflurane and sufentanil | Placebo comparator | Drug: sevoflurane and sufentanilTCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS < 60 |
Who may qualify
- Ages
- 19 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients undergoing cardiac valve repair or replacement surgery under moderate hypothermic cardiopulmonary bypass (CPB).
- All patients should provide written informed consents
Key exclusion criteria (20 listed)
- Preoperative exclusion criteria
- urgent or emergent surgery,
- left ventricle (LV) ejection fraction < 50%,
- application of intraaortic balloon pump (IABP),
- myocardial infarction,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RemifentanilAlso: ultiva, GSKadministering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance | Drug | Remifentanil |
| sevoflurane and sufentanilAlso: sevorane and sufentaladministering sevoflurane and sufentanil for anesthesia maintenance | Drug | sevoflurane and sufentanil |
Primary outcome
time to achieving BIS>80
Time frame: 5 min
The duration from the end of surgery to the time of achieving BIS score > 80 (BIS>80 persisting > 3 min)
2 secondary outcomes
time to achieve SIMV ventilation mode
Time frame: 5 min
time to achieve extubation
Time frame: 5 min
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2020.
Related trials for Cardiovascular Disease
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tae-Yop Kim, MD, PhD principal investigator
Konkuk Univeristy Medical Center
Questions about this trial
What is this clinical trial studying?
A study testing Remifentanil and sevoflurane and sufentanil in people with Cardiovascular Disease, run by Konkuk University Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
time to achieving BIS>80 (time frame: 5 min). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2020.